- Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Janux Therapeutics Announces Proposed Public Offering of Common Stock
- Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
- Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
More ▼
Key statistics
As of last trade Janux Therapeutics Inc (JANX:NMQ) traded at 47.54, -19.00% below its 52-week high of 58.69, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.08 |
---|---|
High | 48.23 |
Low | 46.51 |
Bid | 47.59 |
Offer | 47.94 |
Previous close | 47.10 |
Average volume | 691.08k |
---|---|
Shares outstanding | 51.66m |
Free float | 44.54m |
P/E (TTM) | -- |
Market cap | 2.43bn USD |
EPS (TTM) | -1.34 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 17:03 BST.
More ▼